Success Metrics

Clinical Success Rate

80.0%

Based on 8 completed trials

Completion Rate

80%(8/10)

Active Trials

3(16%)

Results Posted

125%(10 trials)

Terminated

2(11%)

Phase Distribution

Ph not_applicable

Ph phase_3

21%

Ph phase_4

26%

Ph phase_1

16%

Ph phase_2

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution15 total trials

Phase 1Safety & dosage

3(20.0%)

Phase 2Efficacy & side effects

2(13.3%)

Phase 3Large-scale testing

4(26.7%)

Phase 4Post-market surveillance

5(33.3%)

N/ANon-phased studies

1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(8)

Terminated(3)

Other(5)

Detailed Status

Completed8

unknown5

Recruiting3

Terminated2

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Phase 13 (20.0%)

Phase 22 (13.3%)

Phase 34 (26.7%)

Phase 45 (33.3%)

N/A1 (6.7%)

Trials by Status

recruiting316%

withdrawn15%

unknown526%

completed842%

terminated211%

Recent Activity

3 active trials

Showing 5 of 19

completedphase_1

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

NCT04223752

recruitingphase_4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

NCT07004049

recruitingphase_4

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

NCT06342115

recruitingnot_applicable

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

NCT06422533

unknownphase_4

Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

NCT06035055

View all 19 trials

Clinical Trials (19)

Showing 19 of 19 trials

NCT04223752Phase 1

Safety and Pharmacokinetics of Ceftolozane/Tazobactam in Pediatric Participants With Nosocomial Pneumonia (MK-7625A-036)

Completed

NCT07004049Phase 4

Optimising TREATment for Severe Gram-Negative Bacterial Infections

Recruiting

NCT06342115Phase 4

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

Recruiting

NCT06422533Not Applicable

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Recruiting

NCT06035055Phase 4

Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis

Unknown

NCT03217136Phase 2

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Completed

NCT03230838Phase 2

MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)

Completed

NCT03830333Phase 3

Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)

Completed

NCT04238390Phase 3

Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection

Withdrawn

NCT03002506Phase 4

Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns

Terminated

NCT03309657Phase 1

Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid

Completed

NCT02421120Phase 4

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

Completed

NCT02070757Phase 3

Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)

Completed

NCT04352855

Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.

Unknown

NCT04257812

Monitoring of Ceftolozane-Tazobactam Plasmatic Levels in Critical Patients

Unknown

NCT04196608

In Vitro Activity of Ceftolozane/Tazobactam and Imipenem/Relebactam in Clinical Isolates of Pseudomonas Aeruginosa and Enterobacterales Collected From Hematology and Oncology Patients

Unknown

NCT02620774Phase 1

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

Completed

NCT01853982Phase 3

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

Terminated

NCT03510351

Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections

Unknown

All 19 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 19